UnitedHealth Group (UNH) Earns “Buy” Rating from Raymond James Financial

UnitedHealth Group (NYSE:UNH)‘s stock had its “buy” rating reaffirmed by Raymond James Financial in a research report issued on Wednesday.

Other research analysts have also recently issued research reports about the company. Jefferies Group boosted their price objective on UnitedHealth Group from $215.00 to $225.00 and gave the stock a “buy” rating in a research note on Friday, October 13th. Zacks Investment Research upgraded UnitedHealth Group from a “hold” rating to a “buy” rating and set a $219.00 price objective on the stock in a research note on Thursday, September 21st. ValuEngine upgraded UnitedHealth Group from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. Cantor Fitzgerald restated a “buy” rating on shares of UnitedHealth Group in a research note on Tuesday, August 29th. Finally, Leerink Swann restated a “buy” rating and set a $240.00 price objective (up previously from $225.00) on shares of UnitedHealth Group in a research note on Wednesday, October 18th. Three research analysts have rated the stock with a hold rating and twenty-four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $224.56.

Shares of UnitedHealth Group (UNH) traded down $1.33 on Wednesday, hitting $220.09. The company’s stock had a trading volume of 3,246,300 shares, compared to its average volume of 3,119,193. The firm has a market capitalization of $214,570.92, a PE ratio of 23.07, a PEG ratio of 1.64 and a beta of 0.66. UnitedHealth Group has a 12 month low of $156.09 and a 12 month high of $231.77. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.70 and a current ratio of 0.70.

UnitedHealth Group (NYSE:UNH) last issued its quarterly earnings data on Tuesday, October 17th. The healthcare conglomerate reported $2.66 EPS for the quarter, topping the Zacks’ consensus estimate of $2.57 by $0.09. The company had revenue of $50.32 billion for the quarter, compared to analysts’ expectations of $50.38 billion. UnitedHealth Group had a return on equity of 21.52% and a net margin of 4.50%. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.17 earnings per share. analysts predict that UnitedHealth Group will post 9.99 EPS for the current year.

In related news, Director Kenneth Irwin Shine sold 457 shares of the business’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $211.03, for a total value of $96,440.71. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gail R. Wilensky sold 5,600 shares of the business’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $223.31, for a total value of $1,250,536.00. Following the completion of the sale, the director now directly owns 61,137 shares of the company’s stock, valued at $13,652,503.47. The disclosure for this sale can be found here. Over the last three months, insiders sold 57,606 shares of company stock valued at $11,566,525. 0.89% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. grew its holdings in shares of UnitedHealth Group by 1.2% during the second quarter. BlackRock Inc. now owns 69,430,416 shares of the healthcare conglomerate’s stock valued at $12,873,786,000 after purchasing an additional 796,654 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of UnitedHealth Group by 2.5% during the second quarter. Vanguard Group Inc. now owns 64,578,618 shares of the healthcare conglomerate’s stock valued at $11,974,168,000 after purchasing an additional 1,588,516 shares during the last quarter. FMR LLC grew its holdings in shares of UnitedHealth Group by 2.1% during the second quarter. FMR LLC now owns 56,101,668 shares of the healthcare conglomerate’s stock valued at $10,402,371,000 after purchasing an additional 1,168,324 shares during the last quarter. State Street Corp grew its holdings in shares of UnitedHealth Group by 2.5% during the first quarter. State Street Corp now owns 45,724,509 shares of the healthcare conglomerate’s stock valued at $7,499,276,000 after purchasing an additional 1,122,534 shares during the last quarter. Finally, Alliancebernstein L.P. grew its holdings in shares of UnitedHealth Group by 2.3% during the second quarter. Alliancebernstein L.P. now owns 7,906,936 shares of the healthcare conglomerate’s stock valued at $1,466,104,000 after purchasing an additional 174,290 shares during the last quarter. 86.20% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “UnitedHealth Group (UNH) Earns “Buy” Rating from Raymond James Financial” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://stocknewstimes.com/2017/12/06/unitedhealth-group-unh-earns-buy-rating-from-raymond-james-financial.html.

About UnitedHealth Group

UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.

Analyst Recommendations for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply